CClinicalTrials.gg
CompletedNCT02463292Updated Jun 14, 2016

Quality of Life in Young Adults With Congenital Heart Disease

An observational study in Congenital Heart Disease, sponsored by University Children's Hospital, Zurich. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2016-06-14.

Sponsored by University Children's Hospital, Zurich · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
325
Ages
18 Years to 30 Years
Sex
All
01

Study summary

This study aims to evaluate the psychosocial situation of adult congenital heart disease (CHD) patients in terms of health-related quality of life, mental health, academic achievement, and employment status. By assessing a wide variety of medical (e.g., disease severity) and psychosocial (e.g., life events, coping strategies, personality) risk factors it will be possible to better understand the variables that influence psychosocial outcome of young adults with congenital heart disease. This will further improve the understanding of the lifelong consequences of a congenital heart malformation. Factors that proof to be predictors of favorable outcome represent a resource of resilience and therefore should play an important role in the care of CHD patients. By implementing those results in patient care the investigators aim to achieve an improved psychosocial outcome among adult congenital heart disease (ACHD).

Hypothesis 1: It is expected that perceived health status, health-related quality of life and psychological adjustment will not differ between the patient and the control group. However, academic achievement and employment status are expected to be poorer in young adults with congenital heart disease compared to healthy controls.

Hypothesis 2: It is assumed that parental socioeconomic status, problems in emotional regulation and impaired social support will be related to a negative psychosocial outcome and health-related quality of life. Moreover, the investigators hypothesize that disease severity is associated with academic outcome and employment status.

Read the detailed description

Background: With an incidence of 6 in 1000 live born children congenital heart disease is among the most common birth defects. Survival rates of children with CHD have significantly improved during the past decades due to better surgical and intensive care medicine. Nowadays, even children requiring open- heart surgery for CHD most frequently have a good cardiac outcome and survive into adulthood. Even those with the most complex forms of CHD have sufficient cardiac outcome. However, impaired quality of life, mental health and behavior problems, as well as neurocognitive and motor impairments have been described to occur more frequently in children with CHD compared to healthy children and may persist into adolescence.

Current findings on QoL, psychological adjustment, and academic achievements in young adults with CHD are currently quite inconsistent due to methodological reasons. Moreover, little is known on risk factors for a negative outcome. To date, mainly medical risk factors have been examined while psychosocial characteristics (e.g., socioeconomic status, parenting, family characteristics) have not been systematically studied. Importantly, little is known about academic achievements and employment situations of young adults with CHD.

Aims: In this study the investigators aim to evaluate the psychosocial situation of adult CHD patients in terms of health-related quality of life, mental health, academic achievement, and employment status.

Methods: The study is designed as a case-control study beeing a mono-center project. The patient group will consist of a maximum of 350 patients with congenital heart disease treated at the cardiologic department of the University Hospital Zurich and a control group consisting of the same amount of also up to 350 individuals beeing good friends of the patients with same gender and similar age.

Recruitment: Participants will be consecutively recruited from May 1st, 2015 to April 30th, 2016. Eligible patients will be contacted by the study nurse during the outpatient consultation at the university hospital. Patients will be informed about the study during their consultation by the study nurse as well as the doctor with whom they have their appointment.The control group will be recruited as good friends (same gender, approx. same age) of the patients.

02

Conditions studied

  • Congenital Heart Disease

Keywords

  • quality of life
  • young adults
  • congenital heart disease
03

In context

Heart Diseases

3,640 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's enrollment of 325 is above the median of 294 across 1,241 observational studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

University Children's Hospital, Zurich is the lead sponsor of 92 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Yound adult patients with congenital heart disease

Inclusion criteria

  • Congenital heart disease (Tetralogy of Fallot, Transposition of the great arteries, univentricular heart disease, ventricular septal defect) treated at the University hospital Zurich.
  • Male and Female subjects 18 years to 30 years of age
  • Written informed consent by the participant after information about the project
  • In command of the German language

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a chromosomal or genetic syndrome as well as other congenital or acquired neurological impairments leading to mental disorders
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
325 participants (actual)
Patient registry
No

Groups and cohorts

  • patient group

    The patient group will consist of a maximum of 350 patients (male and female subjects,18 years to 30 years of age, in command of the German language)) with congenital heart disease (Tetralogy of Fallot, Transposition of the great arteries, univentricular heart disease, ventricular septal defect) treated at the cardiologic department of the University Hospital Zurich. Eligible patients will be contacted by the study nurse during the outpatient consultation at the university hospital. No intervention.

    Other: no intervention

  • peer control group

    The control group will be recruited as good friends (same gender, approx. same age of the patients, in command of the German language). The patients will be given a study information for controls to hand this to their good friend and ask the friend to contact the study nurse for participation in the study. No intervention.

    Other: no intervention

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Health related Quality of life

    Health related Quality of life will be assessed by the SF-36 questionnaire (Bullinger \& Kirchberger, 1998).

    Time frame: up to 12 months

Secondary outcomes

  1. Psychological adjustment

    Psychological adjustment will be assessed by the symptom checklist-27 (SCL-27).

    Time frame: up to 12 months

  2. Academic achievement / employment situation

    Academic achievement / employment situation will be assessed by means of a self-developed questionnaire: Participants will be asked to give information on their own education by means of number of school years, number of school year repetitions, type of schooling, need for special schooling or tutoring, age at graduation from school, completed apprenticeship and current employment status.

    Time frame: up to 12 months

  3. Medical data

    Medical data will be collected only for the patients from their medical records: Exact cardiac diagnosis, number of surgeries on cardio-pulmonary bypass, number of interventional procedures, current functional class (according to the New Your Heart Association functional class), biometric characteristics (body weight, height, body mass index), current clinical findings (oxygen saturation, respiratory rate, heart rate, blood pressure), current medication, previous cardiovascular complications (arrhythmias, heart failure, endocarditis, stroke), current echocardiographic findings (ventricular function, residual valve regurgitation or stenosis, residual shunts), data from exercise testing (maximal exercise capacity, maximal oxygen uptake, heart rate reserve), findings from cardiac catheterization and cardiac MRI or CT, if available.

    Time frame: up to 12 months

  4. Executive functions

    Executive functions will be measured with the dysexecutive questionnaire (DEX) (Wilson, Alderman, Burgess, Emslie, \& Evans, 1996).

    Time frame: up to 12 months

  5. Major life events

    Major life events will be assessed for the previous 12 months by a 12-item scale regarding for example unemployment, change of domicile, death of family members or friends (Landolt \& Vollrath, 1998).

    Time frame: up to 12 months

  6. Social support

    Social support will be assessed by means of the the F-SozU, a 14-item short form questionnaire assessing subjectively perceived emotional and instrumental support as well as social integration (Fydrich, Sommer \& Brähler, 2002).

    Time frame: up to 12 months

  7. Emotional regulation

    Emotional regulation is measured with the FEEL-E, an inventory that assesses 12 strategies (6 adaptive, 6 maladaptive) for regulation of temper, fear and grief (Grob \& Horowitz, 2014).

    Time frame: up to 12 months

  8. Socioeconomic status

    Socioeconomic status will be calculated by means of a 6-point scale scoring for paternal occupation and maternal education.

    Time frame: up to 12 months

  9. Biographical information

    Participants will be asked to give information on their family status, own children, citizenship, mother tongue and parents'mother tongue on the same questionnaire they fill out information about education and academic career.

    Time frame: up to 12 months

07

Study locations

1 site
  • UniversityHospital Zurich
    Zurich, 8091, Switzerland
08

References and documents

Publications

  • Bullinger, M. & Kirchberger, I. (1998). SF-36 Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe.
  • Burgess, P. W., Alderman, N., Wilson, B. A., Evans, J. J., & Emslie, H. (1996). The dysexecutive Questionnaire. In B. A. Wilson, N. Alderman, P. W. Burgess, H. Emslie, & J. J. Evans (Eds.), Behavioral assessment of the dysexecutive syndrome. Bury St. Edmunds, UK: Thames Valley Test Company.
  • Landolt, M.A. & Vollrath, M.E. (1998). Life Event Scale. Zurich: University Children's Hospital.
  • Fydrich, T., Sommer, G., & Brähler, E. (2007). Fragebogen zur sozialen Unterstützung (F-SozU). Göttingen: Hogrefe.
  • Grob, A. & Horowitz, L.M., Fragebogen zur Erhebung der Emotionsregulation bei Erwachsenen (FEELE). (2010). Bern: Huber
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02463292
Lead sponsor
University Children's Hospital, Zurich
Responsible party
Markus A. Landolt (Prof. Markus Landolt, PhD, University Children's Hospital, Zurich) — Principal investigator
First posted
Jun 4, 2015
Start date
May 2015
Primary completion
May 2016
Completion
May 2016
Last update
Jun 14, 2016

Study contacts

Markus Landolt, PHD
principal investigator · University Children's Hospital, Zurich

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion